Analysts are intrested in these 5 stocks: ( (CTXR) ), ( (AMT) ), ( (JAZZ) ), ( (CTMX) ) and ( (FATE) ). Here is a breakdown of their recent ratings and the rationale behind them.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Citius Pharmaceuticals is catching analysts’ attention as Lymphir’s launch gathers steam, even after a temporary dip in early sales. Swayampakula Ramakanth has initiated coverage with a Buy rating and a $4 price target, arguing that broad insurance coverage, strong formulary adoption, and the first European shipment point to a promising commercial trajectory.
The story hinges on Lymphir’s differentiated way of attacking cutaneous T‑cell lymphoma, which could let it carve out share from established players like Adcetris and Poteligeo. With Citius still holding around 71% of its oncology spin-out and two more late‑stage candidates waiting on funding, the analyst projects a steady ramp toward peak Lymphir sales of roughly $156 million by 2031.
American Tower is being recast as a classic “quality on sale” opportunity after a sharp derating has pushed its valuation to a five‑year low. Madison Rezaei upgraded the stock to Buy with a $207 target, noting that the market is fixated on macro and technology risks while ignoring steady fundamentals and the company’s long record as a compounder.
Concerns around satellite competition, interest rates, and Dish‑related churn are seen as overblown, with American Tower actively managing debt, benefiting from potential wireless partnerships, and backed by an FCC escrow that cushions lost Dish revenue. On 15.2x next‑twelve‑month AFFO and a target multiple of 18x on 2027 estimates, the analyst argues this is an attractive entry point for long‑term income and growth.
Jazz Pharmaceuticals is being re‑rated as a growth story again, powered by excitement around oncology drug Ziihera and better‑than‑feared performance in its legacy sleep franchise. Ashwani Verma has upgraded JAZZ to Buy and lifted the price target sharply to $307, citing stronger execution in late 2025 and early 2026 and a robust Phase 3 dataset in gastric and esophageal cancer.
The analyst now sees Jazz delivering low double‑digit revenue and EPS growth from 2026 to 2030, driven mainly by Ziihera’s ramp to an estimated $3.1 billion in peak sales across gastric, esophageal, and breast cancer. With Modeyso also trending ahead of earlier expectations and sleep and Epidiolex remaining resilient, Verma argues that improved visibility and catalysts from approvals and label expansions could justify a higher earnings multiple.
CytomX Therapeutics has re‑entered the spotlight with what one analyst sees as a rare, high‑upside colorectal cancer asset hiding in plain sight. Kalpit Patel has initiated coverage with a Buy rating and a $6 target, highlighting that Varseta‑M, an EpCAM‑targeting ADC, is showing response rates roughly five times higher than current standard options in heavily pretreated patients.
Safety is the key debate, particularly serious diarrhea, but updated dosing strategies and prophylaxis appear to be bringing side effects into a range comparable with other commercial cancer drugs. With shares weak since the last update, upcoming clinical data, FDA discussions on a registrational path, and bevacizumab combination results over the next year are framed as catalysts that could unlock value if the efficacy and safety profile holds.
Fate Therapeutics is being positioned as an early leader in a new wave of off‑the‑shelf cell therapies for autoimmune disease rather than a traditional oncology play. Roger Song has initiated coverage at Buy with a $4 price target, arguing that the lead iPSC‑derived CD19 CAR‑T, FT819, could offer lupus patients a more convenient and scalable alternative to bespoke autologous CAR‑T treatments.
The analyst sees FT819’s potential in severe lupus nephritis and extra‑renal lupus as the main value driver, with Phase 2 pivotal work starting in 2026 and several key readouts through 2027 to test whether efficacy can approach current CAR‑T benchmarks with better safety and outpatient delivery. With a multi‑asset pipeline, ample cash runway into 2028, and a flexible pricing angle, Fate is presented as a higher‑risk, higher‑reward bet on the future of allogeneic cell therapies in autoimmunity.